HEART UK OFFERS GUIDANCE ON THE SAFE USE OF LIPID LOWERING THERAPY DURING COVID-19 PANDEMIC
Patients with atherosclerotic cardiovascular disease (ASCVD) and obesity are at increased risk of severe illness and mortality if infected with COVID-19.
In the absence of evidence from a high-quality clinical trial, a consensus statement by HEART UK, based on available evidence and experts’ opinion, provides a guide for managing hyperlipidaemia during the pandemic.